Usefulness of B natriuretic peptides and procalcitonin in emergency medicine

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 203-217

  Delerme, S ^a,b   Chenevier Gobeaux, C ^c   Doumenc, B ^d,e   Ray, Patrick ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

BNP; Community acquired pneumonia; Dyspnea; Emergency department; Heart failure; NT proBNP; Septic shock

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PROCALCITONIN;

ASEPTIC MENINGITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PERITONITIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DYSPNEA; EMERGENCY MEDICINE; FEVER; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 41949111706     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s499     Document Type: Review

References (99)

1. Alibay, Y., Beauchet, A., El Mahmoud, R. et al. 2004. Analytical correlation between plasma N.-terminal, pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. Clin. Biochem., 37(10):933-6.
2. Alibay, Y., Beauchet, A., El Mahmoud, R. et al. 2005. Plasma N-terminal pro-brain-natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed. Pharmacother, 59(1-2):20-4.
3. Anand-Srivastava, M.B. 2005. Natriuretic peptide receptor-C signaling and regulation. Peptides, 26(6):1044-59.
4. Anwaruddin, S., Lloyd-Jones, D.M., Baggish, A. et al. 2006. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J. Am. Coll., Cardiol., 47(1):91-7.
5. Arques, S., Roux, E., Sbragia, P et al. 2005. B-type natriuretic peptide and tissue Doppler study findings in elderly patients hospitalized for acute diastolic heart failure. Am. J. Cardiol., 96(1):104-7.
6. Austin, W.J., Bhalla, V., Hernandez-Arce, I. et al. 2006. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am. J. Clin. Pathol., 126(4):506-12.
7. Bayes-Genis, A., Lopez, L., Zapico, E. et al. 2005. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J. Card Fail, 11 (5 Suppl):S3-8.
8. Bayes-Genis, A., Santalo-Bel, M., Zapico-Muniz, E. et al. 2004. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J. Heart Fail, 6(3):301-8.
9. Berdague, P., Caffin, P.Y., Barazer, I. et al. 2006. Use of N-terminal prohomone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am. Heart J., 151(3):690-8.
10. Bernard, L., Ferriere, F., Casassus, P. et al. 1998. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin. Infect. Dis., 27(4):914-5.
11. Binder, L., Pieske, B., Olschewski, M. et al. 2005. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation, 112(11):1573-9.
12. Boussekey, N., Leroy, O., Georges, H. et al. 2005. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired. pneumonia in an intensive care unit. Infection, 33(4):257-63.
13. Cabanes, L., Richaud-Thiriez, B., Fulla, Y. et al. 2001. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest, 120(6):2047-50.
14. Caterino, J.M., Scheatzle, M.D., Forbes, M.L. et al. 2004. Bacteremic elder emergency department patients: procalcitonin and white count. Acad. Emerg Med., 11(4):393-6.
15. Chan, Y.L., Tseng, C.P., Tsay, P.K. et al. 2004. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit. Care, 8(1):R.12-20.
16. Chenevier-Gobeaux, C., Allo, J.C., Arthaud, M. et al. 2008. NT-proBNP testing for short-term prognosis in breathless elderly patients. Am. J. Emerg. Med. In press.
17. Chenevier-Gobeaux, C., Claessens, Y.E., Voyer, S. et al. 2005. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin. Chim. Acta., 361(1-2):167-75.
18. Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R. et al. 2004. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet, 363(9409):600-7.
19. Christ-Crain, M., Stolz, D., Bingisser, R. et al. 2006. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med., 174(1):84-93.
20. Clec'h, C., Fosse, J.P., Karoubi, P. et al. 2006. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit. Care Med., 34(1):102-7.
21. Clerico, A., Iervasi, G., Del Chicca, M.G. et al. 1998. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J. Endocrinol. Invest., 21(3):170-9.
22. Clerico, A., Recchia, F.A., Passino, C. et al. 2006. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol., 290(1):H17-29.
23. Clyne, B. and Olshaker, J.S. 1999. The C-reactive protein. J. Emerg. Med., 17(6):1019-25.
24. Dan, Q., Krishnaswamy, P., Kazanegra, R. et al. 2001. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll Cardiol., 37(2):379-85.
25. Das, S.R., Drazner, M.H., Dries, D.L. et al. 2005. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation, 112(14):2163-8.
26. Davis, M., Espiner, E., Richards, G. et al. 1994. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet, 343(8895):440-4.
27. de Bold, A.J., Borenstein, H.B., Veress, A.T. et al. 1981. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci., 28(1):89-94.
28. Emdin, M., Passino, C., Del Ry, S. et al. 2003. Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin. Chem. Lab. Med., 41(5):686-92.
29. Gaini, S., Koldkjaer, O.G., Pedersen, C. et al. 2006. Procalcitonin, lipopoly- saccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit. Care, 10(2):R.53.
30. Gegenhuber, A., Mueller, T., Dieplinger, B. et al. 2006. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin. Chim. Acta., 370(1-2):174-9.
31. Guven, H., Altintop, L., Baydin, A. et al. 2002. Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am. J. Emerg. Med., 20(3):202-6.
32. Harbarth, S., Holeckova, K., Froidevaux, C. et al. 2001. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am. J. Respir. Crit. Care Med., 164(3):396-402.
33. Harrison, A., Morrison, L.K., Krishnaswamy, P. et al. 2002. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann. Emerg. Med., 39(2):131-8.
34. Hausfater, P., Garric, S., Ayed, S.B. et al. 2002. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin. Infect. Dis., 34(7):895-901.
35. Hausfater, P., Juillien, G., Madonna-Py, B. et al. 2007. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit. Care, 11(3):R.60.
36. Hedlund, J. and Hansson, L.O. 2000. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection, 28(2):68-73.
37. Hermann-Arnhof, K.M., Hanusch-Enserer, U., Kaestenbauer, T. et al. 2005. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem., 51(1):138-43.
38. Indino, P., Lemarchand, P., Bady, P. et al. 2007. Prospective study on procalcitonin and other systemic infection markers in patients with leukocytosis. Int. J. Infect. Dis.
39. Januzzi, J.L., Camargo, C.A., Anwaruddin, S. et al. 2005. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol., 95(8):948-54.
40. Januzzi, J.L., Peacock, W.F., Maisel, A.S. et al. 2007. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol., 50(7):607-13.
41. Januzzi, J.L., van Kimmenade, R., Lainchbury, J. et al. 2006. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J., 27(3):330-7.
42. Jereb, M., Muzlovic, I., Hojker, S. et al. 2001. Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection, 29(4):209-12.
43. Jones, A.E., Fiechtl, J.F., Brown, M.D. et al. 2007. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann. Emerg. Med., 50(1):34-41.
44. Jorge, S., Becquemin, M.H., Delerme, S. et al. 2007. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc. Disord., 7:16.
45. Knudsen, C.W., Clopton, P., Westheim, et al. 2005. Predictors of elevated B-type natriuretic peptide concentrations ifi dyspneic patients without hearf failure: an analysis from the breathing not properly multinational study. Ann. Emerg Med., 45(6):573-80.
46. Kofoed, K., Andersen, O., Kronborg, G. et al. 2007. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit. Care, 11(2):R38.
47. Kroll, M.H., Twomey, P.J. and Srisawasdi, P. 2007. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin. Chim Acta., 380(1-2):197-202.
48. Komar, A., Roberts, D., Wood, K.E. et al. 2006. Duration of hyprotension before initiation of efferctive antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med., 34(6):1589-96.
49. Lainchbury, J.G., Campbell, E., Frampton, C.M. et al. 2003. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol., 42(4):728-35.
50. Lemiale, V., Renaud, B., Moutereau, S. et al. 2007. A single procalcitonin level does not predict adverse outcomes of women with pyelonephritis. Eur. Urol., 51(5):1394-401.
51. Levin, E.R., Gardner, D.G. and Samson, W.K. 1998. Natriuretic peptides. N. Engl. J. Med., 339(5):321-8.
52. Levy, M.M., Fink, M.P., Marshall, J.C. et al. 2003. 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Intensive Care Med., 29(4):530-8.
53. Lien, C.T., Gillespie, N.D., Struthers, A.D. et al. 2002. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur. J. Heart Fail, 4(1):91-8.
54. Logeart, D., Lecuyer, L., Thabut, G. et al. 2007. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med., 33(2):286-92.
55. Logeart, D., Saudubray, C., Beyne, P. et al. 2002. Comparative value of oppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J. Am. Coll. Cardiol., 40(10):1794-800.
56. Logeart, D., Thabut, G., Jourdain, P. et al. 2004. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol., 43(4):635-41.
57. Loke, I., Squire, I.B., Davies, J.E. et al. 2003. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur. J. Heart Fail, 5(5):599-606.
58. Lubien, E., DeMaria, A., Krishnaswamy, P. et al. 2002. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation, 105(5):595-601.
59. Luzzani, A., Polati, E., Dorizzi, R. et al. 2003. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit. Care Med., 31(6):1737-41.
60. Maeda, K., Tsutamoto, T., Wada, A. et al. 1998. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J., 135(5 Pt 1):825-32.
61. Maeder, M., Fehr, T., Rickli, H. et al. 2006. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest, 129(5):1349-66.
62. Maisel, A.S. 2003. The diagnosis of acute congestive heart failure: role of BNP measurements. Heart Fail Rev., 8(4):327-34.
63. Maisel, A.S., Krishnaswamy, P., Nowak, R.M. et al. 2002. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med., 347(3):161-7.
64. Massaro, K.S., Costa, S.F., Leone, C. et al. 2007. Procalcitonin (PCT) and Greactive Protein (CRP), as severe systemic infection markers in febrile neutropenic adults. BMC Infect. Dis., 7(1):137.
65. McCaig, L.F. and Burt, C.W. 2004. National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary. Adv. Data, (340)1-34.
66. McCullough, P.A., Duc, P., Omland, T. et al. 2003. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Property Multinational Study. Am. J. Kidney Dis., 41(3):571-9.
67. Meisner, M. 2005. Biomarkers of sepsis: clinicatly useful? Curr. Opin. Crit. Care, 11(5):473-80.
68. Moe, G.W., Howlett, J., Januzzi, J.L. et al. 2007. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation, 115(24):3103-10.
69. Morrow, D.A., de Lernos, J.A., Blazing, M.A. et al. 2005. Prognostic value of serial B-type natriuretic peptide testing during follow-up patients with unstable coronary artery disease. Jama, 294(22):2866-71.
70. Mueller, C., Frana, B., Rodriguez, D. et al. 2005a. Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can. J. Cardiol., 21(11):921-4.
71. Mueller, C., Scholer, A., Laule-Kilian, K. et al. 2004. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med., 350(7):647-54.
72. Mueller, T., Gegenhuber, A., Poelz, W. et al. 2005b. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart, 91(5):606-12.
73. Muller, B., Becker, K.L., Schachinger, H. et al. 2000. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit. Care Med., 28(4):977-83.
74. Muller, B., Harbarth, S., Stolz, D. et al. 2007. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect. Dis., 7:10.
75. Ortega, M., Rovira, M., Filella, X. et al. 2004. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br. J. Haematol., 126(3):372-6.
76. Pieralli, F., Olivotto, I., Vanni, S. et al. 2006. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am. J. Cardiol., 97(9):1386-90.
77. Prat, C., Dominguez, J., Andreo, F. et al. 2006. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J. Infect., 52(3):169-77.
78. Ray, P., Arthaud, M., Birolleau, S. et al. 2005. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J. Am. Geriatr Soc., 53(4):643-8.
79. Ray, P., Arthaud, M., Lefort, Y. et al. 2004. Usefulness of B-type natriuretic peptide in elderly patients-with acute dyspnea. Intensive Care Med., 30(12):2230-6.
80. Ray, P., Badarou-Acossi, G., Viallon, A. et al. 2007. Accuracy of the cerebrospinal fluid results to differentiate bacterial from non bacterial meningitis, in case of negative gram-stained smear. Am. J. Emerg Med., 25(2):179-84.
81. Ray, P., Birolleau, S., Lefort, Y. et al. 2006a. Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit. Care, 10(3):R.82.
82. Ray, P., Maziere, F., Medimagh S. et al. 2006b. Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older brief report. Am. J. Emerg. Med., 24(5):603-7.
83. Rihal, C.S., Davis, K.B., Kennedy, J.W. et al. 1995. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am. J. Cardiol, 75(4):220-3.
84. Rivers, E., Nguyen, B., Havstad, S. et al. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic slicick. N. Engl. J. Med.; 345(19):1368-77.
85. Ruskoaho, H. 2003. Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev., 24(3):41-56.
86. Schwarz, S., Bertram, M., Schwab, S. et al. 2000. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit. Care Med., 28(6):1828-32.
87. Shapiro, N.I., Howell, M.D., Talmor, D. et al. 2005. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann. Emerg. Med., 45(5):524-8.
88. Simon, L., Gauvin, F., Amre, D.K. et al. 2004. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis., 39(2):206-17.
89. Spahr, L., Morard, L., Hadengue, A. et al. 2001. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology, 48(38):502-5.
90. Spapen, H.D., Hachimi-Idrissi, S., Come, L. et al. 2006. Diagnostic markers of sepsis in the emergency department. Act. Clin. BeIg., 61(3):138-42.
91. Stolz, D., Christ-Crain, M., Bingisser, R. et al. 2007. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest, 131(1):9-19.
92. Stucker, F., Herrmann, F., Graf, J.D. et al. 2005. Procalcitonin and infection in elderly patients. J. Am. Geriatr. Soc., 53(8):1392-5.
93. Swedberg, K., Cleland, J., Dargie, H. et al. 2005. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J., 26(11):1115-40.
94. Tang, B.M., Eslick, G.D., Craig, J.C. et al. 2007. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect. Dis., 7(3):210-7.
95. Uzzan, B., Cohen, R., Nicolas, P. et al. 2006. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit. Care Med., 34(7):1996-2003.
96. Viallon A., Guyomarc'h, P., Guyomarc'h, S. et al. 2005. Decrease in serum procalcitonin levels over time during treatment of acute bacterial meningitis. Crit. Care, 9(4):R.344-50.
97. Viallon, A., Zeni, F., Lambert, C. et al. 1999. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin.Infect. Dis., 28(6):1313-6.
98. Viallon, A., Zeni, F., Pouzet, V. et al. 2000. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med., 26(8):1082-8.
99. Yasue H., Yoshimura, M., Sumida, H. et al. 1994. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 90(1):195-203.